Axon Enterprise — Feb 25, 2025 release
Fiscal 2024 fourth-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001069183-25-000015
Showing in the filing
Revenue
“$2.55 billion to $2.65 billion”
Period
FY2025
Measure
GAAP-tied
Source
Prose
All guidance in this release · 11
Adjusted EBITDA for FY2025
“$640 million to $670 million”
Adjusted EBITDA dollars for FY2025
“$640 million to $670 million”
Software-only gross margin target for the long term
“80%”
Remainder of future contracted bookings expe… for the long term
“over the following ten years”
Revenue for FY2025
“$2.55 billion to $2.65 billion”
Adjusted EBITDA margin for FY2025
“approximately 25%”
Stock-based compensation expenses for FY2025
“approximately $580 million to $630 million”
Stock-based compensation expense related to … for FY2025
“approximately $325 million”
CapEx for FY2025
“$140 million to $180 million”
Portion of future contracted bookings expect…
“between 20% to 25%”
Moonshot goal to cut gun-related deaths betw… for FY2033
“50%”
Exhibit 99.1 · the passage around this item
… earlier in the release
2025 Outlook The following forward-looking statements reflect Axon’s expectations as of February 25, 2025 and are subject to risks and uncertainties. Please refer to “Forward-looking Statements” below for more information. Full Year • Axon expects full year 2025 revenue of $2.55 billion to $2.65 billion, representing approximately 25% annual growth at the midpoint. • Axon expects full year 2025 Adjusted EBITDA dollars of $640 million to $670 million, representing Adjusted EBITDA margin of approximately 25%. ◦ We provide Adjusted EBITDA guidance, rather than net income guidance, due to the inherent difficulty of forecasting certain types of expenses and gains such as stock-based compensation, income tax expenses and gains or losses on marketable securities and strategic investments, which affect net income but not Adjusted EBITDA. We are unable to reasonably estimate the impact of such expenses, which could be material, on net income. Accordingly, we do not provide a reconciliation of projected net income to projected Adjusted EBITDA • We expect stock-based compensation expenses to be approximately $580 million to $630 million. • Full year stock-based compensation expense includes approximately $325 million, related to the broad-based 2024 eXponential Stock Plan and the 2024 CEO Performance Award, primarily in SG&A and R&D. These performance-based incentive programs are achieved through stock price, operational and time-based requirements and are divided into seven substantially e
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.